Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PerELISA: Neoadjuvant Pertuzumab, Trastuzumab, and Letrozole in HER2+/HR+ Breast Cancer
NCT02411344Phase 2Completed
- Sponsor
- Istituto Oncologico Veneto
- Start
- Feb 2014
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab in breast cancer, sponsored by Istituto Oncologico Veneto. Started Feb 2014; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02411344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411344.